A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2018
Price : $35 *
At a glance
- Drugs Siponimod (Primary)
- Indications Dermatomyositis; Multiple sclerosis; Polymyositis; Renal impairment
- Focus Pharmacokinetics
- Sponsors Novartis
- 14 Nov 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics
- 03 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 07 Jan 2015 Planned End Date changed from 1 Jan 2015 to 1 Jul 2015 according to ClinicalTrials.gov record.